Esperion reports preliminary 2025 revenue up 20-23%, U.S. sales up 35-38%; provides 2026 OpEx guidance

Esperion Therapeutics, Inc.

2025-FY EPS reported -$0.11 revenue$403,135,000

Preliminary 2025 U.S. net product sales $156-160M, up 35-38% YoY; total revenue $400-408M, up 20-23%.
Cash and equivalents ~$168M at year-end 2025; completed $75M capital raise in 2025.
2026 operating expenses expected $210-245M, including $15M non-cash stock compensation.
Patent settlements with four ANDA filers restrict generic entry until April 2040; no remaining patent challenges.
R&D pipeline: nominated ESP-2001 (ACLY inhibitor) for primary sclerosing cholangitis; blockbuster potential >$1B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.